Compare OVV & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVV | NBIX |
|---|---|---|
| Founded | 2020 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 13.2B |
| IPO Year | 2019 | 1996 |
| Metric | OVV | NBIX |
|---|---|---|
| Price | $61.18 | $130.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 22 |
| Target Price | $58.35 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | 13.54 | ★ 41.95 |
| EPS | ★ 4.78 | 4.67 |
| Revenue | ★ $8,908,000,000.00 | $161,626,000.00 |
| Revenue This Year | $5.45 | $24.73 |
| Revenue Next Year | N/A | $13.14 |
| P/E Ratio | ★ $12.23 | $27.48 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $33.26 | $105.50 |
| 52 Week High | $62.60 | $160.18 |
| Indicator | OVV | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 51.13 |
| Support Level | $36.80 | $124.62 |
| Resistance Level | $62.60 | $135.88 |
| Average True Range (ATR) | 1.36 | 3.58 |
| MACD | 0.29 | -0.12 |
| Stochastic Oscillator | 99.90 | 59.98 |
Ovintiv Inc is a North American oil and natural gas exploration and production company focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs, and natural gas. The company has two operating segments: USA Operations and Canadian Operations. USA Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within the United States. Canadian Operations include the exploration, development, production, and marketing of oil, NGLs, natural gas, and other related activities within Canada. The company generates the majority of its revenue from USA Operations.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.